uniQure N.V.
NASDAQ:QUREBiotechnology
-$1.13 today
- Market cap
- $1.42B
- Beta
- 1.00
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$3.33
Volume 1.13M
Average 1.75M
QURE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
uniQure N.V.NASDAQ: QURE
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $29.18M fell 19.3% year over year, behind the -4.7% change in trailing-twelve-month research & development. Sequentially, it fell 13.8% from the prior quarter. Over 3 fiscal years it compounded at -10.7% a year.
Context
- Research & development amounted to 873.9% of revenue in FY2025, up 343.7 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -19.3% toward the trailing-twelve-month pace of -4.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 140.67M USD
- Year-over-year change
- -2.2%
- 4-year CAGR
- -0.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.67M | -2.2% |
| FY2024 | 2024-12-31 | 143.78M | -33.1% |
| FY2023 | 2023-12-31 | 214.86M | +8.7% |
| FY2022 | 2022-12-31 | 197.59M | +37.6% |
| FY2021 | 2021-12-31 | 143.55M | — |
Research & Development vs competitors
How QURE compares with its peers on the latest reported figures
- QURE's LTM Mar 2026 research & development of $132.76M is the 5th highest of the 8 companies compared; the peer median is $137.53M.
- Its year-over-year change of -4.7% is the 7th highest of 8, against a peer median of +12.5%.
- Research & development amounts to 733.7% of revenue for QURE, versus a peer median of 249.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Mar 2026 | $228.65M | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $132.76M | -4.7% | -10.7% | 733.7% | |
| LTM Mar 2026 | $128.82M | +9.2% | +14.8% | 161.5% | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $82.4M | +26.5% | +16.4% | — | |
| Peer median (excluding QURE) | $137.53M | +12.5% | +14.8% | 249.3% | |
Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 524M | 106.48M | 15.84M | 27.12M | 16.1M |
| Cost of Revenue | 24.98M | 3.34M | 13.63M | 18.33M | 1.69M |
| Gross Profit | 499.03M | 103.14M | 2.22M | 8.79M | 14.41M |
| Gross Margin | 95.2% | 96.9% | 14.0% | 32.4% | 89.5% |
| Research & Development | 143.55M | 197.59M | 214.86M | 143.78M | 140.67M |
| Selling, General & Admin | 56.29M | 54.7M | 73.08M | 50.68M | 65.34M |
| Operating Expenses | 188.41M | 246.3M | 285.09M | 193.09M | 202.24M |
| Depreciation & Amortization | 7.3M | 8.54M | 11.9M | 12.64M | 14.76M |
| EBITDA | 319M | (108.02M) | (253.1M) | (160.75M) | (116.59M) |
| EBITDA Margin | 60.9% | -101.4% | -1597.6% | -592.7% | -724.2% |
| Operating Income | 310.62M | (143.16M) | (282.87M) | (184.29M) | (187.83M) |
| Operating Margin | 59.3% | -134.4% | -1785.5% | -679.6% | -1166.8% |
| Interest Income | 162K | 609K | 19.56M | 21.42M | 16.97M |
| Interest Expense | 7.47M | 11.7M | 41.56M | 63.74M | 61.99M |
| Other Income / Expenses | 22.19M | 14.9M | (23.69M) | (52.83M) | (5.51M) |
| Income Before Tax | 332.81M | (128.26M) | (306.56M) | (237.13M) | (193.34M) |
| Pre-Tax Margin | 63.5% | -120.5% | -1935.0% | -874.4% | -1201.0% |
| Income Tax Expense | 3.22M | (1.47M) | 1.92M | 2.43M | 5.63M |
| Net Income | 329.59M | (126.79M) | (308.48M) | (239.56M) | (198.97M) |
| Net Margin | 62.9% | -119.1% | -1947.1% | -883.4% | -1236.0% |
| EPS (Basic) | 7.17 | (2.71) | (6.47) | (4.92) | (3.46) |
| EPS (Diluted) | 7.04 | (2.71) | (6.47) | (4.92) | (3.46) |
| Weighted Avg Shares | 45.99M | 46.74M | 47.67M | 48.65M | 57.5M |
| Weighted Avg Shares (Diluted) | 46.84M | 46.74M | 47.67M | 48.65M | 57.5M |
uniQure N.V.
NASDAQ:QURE
Intrinsic Alpha fair value
Locked
Current Price
$20.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.